Seethru Equity Comments on Atossa Genetics Inc.’s FY2016 Earnings (ATOS)
Atossa Genetics Inc. (NASDAQ:ATOS) – Analysts at Seethru Equity raised their FY2016 earnings estimates for shares of Atossa Genetics in a report issued on Monday. Seethru Equity analyst A. Tandon now expects that the firm will post earnings per share of ($2.96) for the year, up from their previous estimate of ($3.60).
Shares of Atossa Genetics (NASDAQ:ATOS) opened at 2.03 on Wednesday. The company’s market capitalization is $5.35 million. The company’s 50-day moving average price is $2.52 and its 200-day moving average price is $3.94. Atossa Genetics has a one year low of $1.78 and a one year high of $12.60.
Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings results on Friday, August 12th. The company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.02.
Atossa Genetics Company Profile
Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.
Receive News & Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.